RCS - Diaceutics PLC - Diaceutics Announces Key Leadership Appointment

DiaceuticsAnnouncement

29/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250729:nRSc6638Sa&default-theme=true

RNS Number : 6638S  Diaceutics PLC  29 July 2025

Reach

Diaceutics Announces Key Leadership Appointment

Lauren DeWitt appointed General Counsel and Group Company Secretary

New York, Belfast and London, 29 July 2025 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical and biotech industries, today announced the
appointment of Lauren DeWitt as Executive Vice President, Legal, General
Counsel, and Group Company Secretary. She will be based at the company's U.S.
headquarters.

Lauren brings extensive legal and leadership experience in the pharmaceutical
sector. Most recently, she served as Vice President and Head of General Legal
at Sandoz, where she led a team of senior attorneys supporting all facets of
the U.S. business, including commercial, regulatory, quality, medical affairs,
and compliance.

Earlier in her career, Lauren held several key legal roles at
both Sandoz and Novartis, including Global Head of Legal BD&L for
Novartis Group, where she oversaw complex global transactions and strategic
partnerships. She began her legal career as a litigator, representing
healthcare and life sciences companies in product liability and general
litigation matters.

Ryan Keeling, Chief Executive Officer of Diaceutics commented: "Lauren brings
deep expertise across litigation, regulatory, and transactional legal
functions, along with a strategic mindset that aligns perfectly with our
growth ambitions. Her proven track record in leading high-impact legal teams
and navigating complex global transactions makes her an invaluable addition to
our leadership team."

Lauren DeWitt, EVP Legal, General Counsel & Group Company Secretary of
Diaceutics commented: "I'm thrilled to be joining Diaceutics at such an
exciting stage of its journey. I was drawn to the company's mission, the
calibre of its legal and compliance work, and the opportunity to make a
meaningful contribution to its continued success. I look forward to leading
the legal function and supporting Diaceutics' strategic growth."

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

About Reach Announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUVSORVRUBUAR